Carnosine And Anti-Ageing
Quick Read Carnosine is a small molecule your muscles naturally produce that declines with age. Research suggests it fights three
Subscribe to the distribution list, to get regular updates on supplement research for health,
🧠 NeuroBright Our evidence-based brain supplement formulated from 1.7M research papers
What if the most important nutritional decision of a pregnancy isn’t folic acid — the supplement everyone knows about — but a fat? Not just any fat, but a specific long-chain omega-3 fatty acid called DHA that your body can barely make on its own, that your growing baby is actively pulling from your bloodstream, and that most prenatal vitamins contain in doses far below what researchers actually recommend?
That’s not a scare story. It’s a genuinely fascinating area of science — one where the research is more nuanced, more conflicted, and ultimately more interesting than the headlines suggest. This post draws on 15 research papers selected by VitacuityAI from an analysis of 1.7 million research papers, specifically for this topic. Here’s what we actually know, what we honestly don’t, and what a sensible, well-informed person might do with all of it.
Let’s start with the biology, because it’s remarkable.
DHA — docosahexaenoic acid — is the dominant omega-3 fatty acid in the human brain. It sits inside the membranes of neurons, influencing how they communicate, how flexible they are, and how efficiently they fire signals. During pregnancy and the early postnatal period, a baby’s brain is developing at extraordinary speed — billions of neurons forming, myelinating (gaining their insulating sheath), and wiring up into the architecture of a mind. This process requires enormous amounts of DHA [8].
The catch is that DHA is what scientists call a “semi-essential” fatty acid. Your body can technically synthesise it from alpha-linolenic acid (ALA), found in flaxseed and walnuts — but the conversion rate is so low as to be almost negligible for most people [4]. The practical upshot: DHA must come from diet or supplements. The richest sources are oily fish and, for those who don’t eat fish, microalgae — the original source that fish get their DHA from in the first place [14].
During pregnancy, the developing baby draws DHA directly from the mother’s bloodstream. Maternal DHA levels are directly reflected in cord blood and breast milk concentration [14]. If a pregnant woman’s intake is low, the fetus still gets what it needs — but at the mother’s expense. This is partly why the old phrase “pregnancy brain” (that foggy, forgetful feeling many pregnant women report) may have a real biological dimension: DHA is being preferentially redirected to the baby [1].
EPA — eicosapentaenoic acid — is the other major marine omega-3. It plays a different role, functioning more as an anti-inflammatory agent and as a precursor to various signalling molecules. Both DHA and EPA are found in fish oil supplements and are considered important in the context of pregnancy nutrition [4] [10].
Evidence grade: Promising — some human RCT data, but results are inconsistent
This is where the science gets genuinely interesting — and genuinely messy.
A systematic review and meta-analysis published in *Nutrition Reviews* (2021) examined 11 randomised controlled trials looking at whether omega-3 supplementation in pregnant and breastfeeding women improved cognitive performance in their children. The headline finding? No statistically significant association was found between DHA/EPA supplementation and any cognitive parameter measured [4].
Before you stop reading — that’s not the whole story. The same review was careful to note that the null result may reflect the limitations of the studies themselves: small sample sizes, difficulty reliably measuring cognition in very young children, and the fact that blood omega-3 levels weren’t comparable across studies. The authors explicitly flagged that “reasons for inconclusive results may be small sample sizes for each assessed category and questionable quality of included studies” [4].
A broader systematic review commissioned to inform the US Dietary Guidelines (published in *Journal of Nutrition*, 2021) took a wider lens — 33 articles from 15 RCTs and one prospective cohort study. Its findings were more encouraging. Of the 8 RCTs that supplemented omega-3 during pregnancy alone (at doses of 200–2,200 mg/day DHA for approximately 20 weeks), 5 out of 8 studies reported at least one finding showing that supplementation improved cognitive development measures in infants or children by 6–11% [6]. That’s a meaningful effect size, even if it’s not dramatic.
The honest caveat: all 8 of those same studies also reported at least one *non-significant* result. So the picture is mixed. The reviewers concluded that there is “limited evidence” that omega-3 supplementation during pregnancy may result in “favourable cognitive development” — a phrase that is carefully chosen and should be read as such [6].
A double-blind RCT from the COPSAC cohort (published in *Child Development*, 2021) specifically supplemented n-3 long-chain polyunsaturated fatty acids versus placebo during the third trimester of pregnancy and followed up on children’s cognition and language development. The study adds to the picture of early-life benefits being plausible but not yet definitively proven [7].
Research using event-related brain potentials — a more sensitive neurophysiological measure than standard cognitive tests — has suggested that prenatal DHA supplementation may influence children’s attention and inhibitory control, two executive functions that develop in the preschool years [3]. This is a promising line of research because it gets around the problem of asking a toddler to do a memory test.
The bottom line on baby brain: the biological rationale is compelling, the animal and mechanistic data are solid, and human trials lean positive — but the evidence base for specific cognitive outcomes is still building. We are not yet in the territory of “proven to make your baby smarter.” We are firmly in the territory of “genuinely promising, biologically plausible, and worth taking seriously” [6] [4].
Evidence grade: Strong — multiple RCTs with consistent findings
This is the area where the omega-3 evidence in pregnancy is arguably at its strongest.
Multiple reviews and trials have found that omega-3 supplementation — particularly DHA and EPA — is associated with a reduced risk of preterm birth [10] [14]. A 2020 narrative review concluded that omega-3s improve “the risk of premature delivery” and described the evidence as supportive across multiple studies [10].
The 2024 review published asking the direct question “Should DHA and EPA Be Mandatory Supplements in Pregnancy?” concluded that supplementation “may reduce the risk of preterm birth” and recommends that supplementation begins before 20 weeks of gestation for maximum benefit [14].
This is not a trivial finding. Preterm birth — delivery before 37 weeks — carries significant risks for infant health, including respiratory, developmental and neurological complications. The fact that a safe, widely available, relatively inexpensive supplement may reduce this risk is one of the more clinically significant omega-3 findings to emerge from pregnancy research [14] [10].
A 2026 study examining commercial prenatal supplements in the US and Canada found that many widely used prenatal vitamins contain omega-3 levels substantially below the amounts used in research trials and below current recommended intakes in pregnancy — meaning that even women who take prenatal supplements may not be getting meaningful doses of DHA [9]. This is an important practical point we’ll return to in the takeaway.
Evidence grade: Conflicted — studies exist, results vary, mechanism is plausible
Postnatal depression (PPD) affects between 10–20% of women, and the question of whether omega-3 supplementation can help prevent or treat it has attracted genuine research interest [13].
The biological logic is sound: the brain — including the parts that regulate mood — is built substantially from DHA. Pregnancy depletes maternal DHA stores. Several neurotransmitter systems implicated in depression rely on fatty acid availability for optimal function [5] [13].
The research, however, is conflicted. A 2023 randomised double-blind placebo-controlled trial of 60 pregnant women (gestational age 22–24 weeks) found no statistically significant difference in Edinburgh Postnatal Depression Scale (EPDS) scores between the omega-3 and placebo groups at any time point during pregnancy or postpartum. However, the omega-3 group showed an *earlier* reduction in EPDS scores, which the authors suggested “may indicate a benefit of antenatal omega-3 supplementation” [12].
A 2023 thematic review drew a more nuanced picture. It examined two key studies side-by-side and found contrasting results: one trial found no significant difference on the EPDS scale (though differences appeared on the BDI scale), while another recorded a significant decrease in depression scores across all dose groups — reductions of 51.5% on the EPDS and 48.8% on the HRSD scale [13]. These are dramatically different findings, and the reviewers concluded that the field needs studies specifically focused on PPD (as distinct from prenatal depression) with better-defined populations and controls [13].
A 2020 review on omega-3 and postpartum depression concluded that the relationship is biologically plausible and that supplementation is low-risk, but that the human evidence remains insufficient for definitive recommendations [5].
Why the conflicted results? Different doses, different timings of supplementation, different population characteristics, different measurement tools, and a failure to distinguish clearly between prenatal depression, perinatal depression, and postnatal depression — which may be distinct conditions with different underlying mechanisms [13].
The overall weight of evidence here: a clear signal is present, but it’s not yet strong enough to say “omega-3 prevents postnatal depression” with confidence. What we can say is that the risk-benefit calculation strongly favours supplementation — it’s safe, has other demonstrated benefits, and the biological plausibility is high.
Evidence grade: Promising — expert consensus emerging but formal dietary reference intakes not yet established
One of the more striking gaps in this field is that formal dietary reference intakes for DHA and EPA in pregnancy have not yet been established [4].
However, several recommendations have emerged from the research:
– Women of childbearing age should aim for 250 mg/day of DHA + EPA from diet or supplements [14] – To reduce the risk of preterm birth, pregnant women should additionally receive at least 100–200 mg of DHA per day [14] – The commonly cited clinical recommendation is 200 mg/day of DHA during pregnancy and breastfeeding, specifically for countries with low seafood consumption [14] – Supplementation should ideally begin before 20 weeks of gestation [14] – The research trials showing cognitive benefits used doses ranging from 200–2,200 mg/day DHA for approximately 20 weeks [6]
The 2026 analysis of prenatal supplements found that many standard prenatal vitamins fall short of even these modest targets [9]. If you’re relying on your standard pregnancy multivitamin to cover omega-3 bases, it’s worth checking the label carefully.
Maternal DHA levels are also reflected in breast milk, meaning that supplementation during lactation continues to matter for the baby’s ongoing brain development [14] [1].
Honesty matters here, because the gap between the biological story and the human evidence is wider than many pregnancy nutrition articles acknowledge.
On baby brain: The most rigorous meta-analysis of RCTs found no statistically significant effect of maternal omega-3 supplementation on children’s cognitive performance [4]. This doesn’t mean there is no effect — it may mean the studies haven’t been good enough to detect one. But we should not overstate the certainty. The 6–11% improvements in cognitive development seen in some trials [6] are real findings, but they come from studies with inconsistent results even within themselves.
On dosing: We still don’t know the optimal dose, timing, or duration of supplementation. Trial doses ranged from 200 mg to 2,200 mg of DHA daily — an enormous range that makes comparisons difficult [6]. The research hasn’t yet identified whether a dose-response relationship exists in humans.
On postnatal depression: Results remain genuinely conflicted. Study quality varies, populations differ, and the distinction between different types of perinatal depression hasn’t been properly controlled for in most trials [13] [12].
On who benefits most: Most trials have studied relatively similar populations. There is a recognised underrepresentation of lower socioeconomic groups, adolescents, and populations with diverse ethnic backgrounds [6]. It’s plausible that women who are already omega-3 deficient benefit most — but this hasn’t been adequately tested.
On blood levels: Across many trials, omega-3 blood levels weren’t measured or compared, making it impossible to know whether supplementation actually raised levels, or whether baseline status affected outcomes [4].
On long-term outcomes: Most studies measure cognitive outcomes at ages 1–6. We have very little data on whether prenatal omega-3 supplementation has lasting effects on school-age cognition, mental health, or brain function in adolescence and adulthood [11].
Let’s apply some practical intelligence here, rather than hiding behind academic hedging.
DHA and EPA are safe. There is no meaningful toxicity risk at the doses used in research (200–2,200 mg/day). These are fats your body is designed to use. The risk of doing nothing — particularly for women who eat little or no oily fish — is almost certainly greater than any conceivable risk from supplementing [14] [10].
Standard prenatal vitamins often don’t cut it. If you’re pregnant or planning to be, check your prenatal supplement label. Many contain little or no DHA [9]. A separate omega-3 supplement — or a prenatal specifically formulated with adequate DHA — is worth considering.
The evidence supports starting before 20 weeks, and ideally before conception if you’re planning a pregnancy. The brain-building window starts early [14].
On mood: If you’re at risk of postnatal depression, or have experienced depression before, the case for supplementing is stronger — not because the evidence is definitive, but because the risk-benefit calculation is clear. Safe, cheap, plausible mechanism, possible benefit. That’s a reasonable reason to act [5] [13].
What would a sensible, informed person actually do?
Aim for 200–300 mg of DHA daily as a minimum, ideally from a dedicated omega-3 supplement rather than relying on your prenatal multivitamin to cover it. If you eat oily fish (salmon, sardines, mackerel) two to three times a week, you may already be getting adequate amounts through diet. If you don’t — and many people in the UK don’t — a daily omega-3 supplement is the practical, safe, and well-supported choice. Continue supplementing during breastfeeding, since breast milk DHA levels depend on maternal intake, and the baby’s brain continues developing rapidly in the first year of life [14] [1].
This is one of those areas where the research, despite its complexity and honest conflicts, points consistently enough in one direction that waiting for perfect certainty would mean missing a real, low-risk opportunity to support both mother and baby.
[1] No title available (2022). Numerous benefits have been associated with omega-3 fatty acid consumption during pregnancy and the postpartum period. DOI: 10.1080/14767058.2020.1786522 | https://pubmed.ncbi.nlm.nih.gov/32643471/
[2] Omega 3 oils and pregnancy (2004). https://pubmed.ncbi.nlm.nih.gov/15124319/
[3] No title available (2022). Docosahexaenoic acid, attention, brain, developmental programming, clinical trial. DOI: 10.1080/1028415X.2020.1712535 | https://pubmed.ncbi.nlm.nih.gov/31957558/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369249/
[4] No title available (2021). Systematic review and meta-analysis of RCTs on DHA/EPA supplementation in pregnant/breastfeeding women and cognitive performance of children. *Nutrition Reviews*. DOI: 10.1093/nutrit/nuaa060 | https://pubmed.ncbi.nlm.nih.gov/32918470/
[5] No title available (2020). Omega-3 fatty acids and postpartum depression. *Journal of Clinical Psychiatry*. DOI: 10.4088/JCP.20com13489 | https://pubmed.ncbi.nlm.nih.gov/32898344/
[6] No title available (2021). Systematic review: omega-3 supplementation during pregnancy/lactation and neurodevelopment in children. 33 articles, 15 RCTs. *Journal of Nutrition*. DOI: 10.1093/jn/nxab238 | https://pubmed.ncbi.nlm.nih.gov/34383914/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764572/
[7] No title available (2021). Double-blind RCT of n-3 LCPUFA supplementation in third trimester of pregnancy; COPSAC cohort; cognition and language development. *Child Development*. DOI: 10.1111/cdev.13541 | https://pubmed.ncbi.nlm.nih.gov/33506965/
[8] No title available (2020). DHA, EPA, brain and heart protective roles. *Current Opinion in Clinical Nutrition & Metabolic Care*. DOI: 10.1097/MCO.0000000000000632 | https://pubmed.ncbi.nlm.nih.gov/32028319/
[9] No title available (2026). Omega-3 levels in commercially available prenatal supplements in the US and Canada compared to recommended intakes. DOI: 10.1055/a-2465-5163 | https://pubmed.ncbi.nlm.nih.gov/39631745/
[10] No title available (2020). Narrative review: omega-3 PUFAs — effects prior to pregnancy, during pregnancy and in offspring cognitive function. DOI: 10.1055/s-0040-1708090 | https://pubmed.ncbi.nlm.nih.gov/32232824/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316866/
[11] No title available (2020). Prenatal micronutrients including omega-3, folic acid, vitamin D and choline in fetal brain development. *Pediatric Discovery*. DOI: 10.1002/ped4.12199 | https://pubmed.ncbi.nlm.nih.gov/32851355/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331361/
[12] No title available (2023). Randomised double-blind placebo-controlled trial; 60 pregnant women; omega-3 supplementation and maternal depressive symptoms from pregnancy to 6 months postpartum. *Nutritional Neuroscience*. DOI: 10.1080/1028415X.2022.2068877 | https://pubmed.ncbi.nlm.nih.gov/35499912/
[13] A Critical Look at Omega-3 Supplementation: A Thematic Review (2023). Omega-3 and postpartum depression; thematic review of RCTs. *Healthcare*. DOI: 10.3390/healthcare11233065 | https://pubmed.ncbi.nlm.nih.gov/38063633/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10705916/
[14] Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) — Should They Be Mandatory Supplements in Pregnancy? (2024). https://pubmed.ncbi.nlm.nih.gov/39062044/
[15] No title available (2022). Systematic review of RCTs: omega-3 effects on brain functions; 9 studies selected from 174 articles. *Cureus*. DOI: 10.7759/cureus.30091 | https://pubmed.ncbi.nlm.nih.gov/36381743/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641984/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Carnosine is a small molecule your muscles naturally produce that declines with age. Research suggests it fights three
Quick Read CoQ10 is a molecule found in your cells’ power stations (mitochondria) that helps convert food into energy your
